100% Tariffs on Drugs: What the Section 232 Pharma Bombshell Means for Importers

The U.S. just imposed a 100% tariff on patented pharmaceutical imports — the steepest Section 232 rate ever applied to a single product category. But the real complexity isn't the headline rate. It's a five-tier system where your duty rate depends on who you are, where you manufacture, and whether you've cut a deal with two different federal agencies. If you import pharmaceuticals, ingredients, or biologics, you have roughly 90 days to figure out where you land.

On April 2, 2026 — exactly one year after the original "Liberation Day" tariffs — President Trump signed a proclamation that turned the pharmaceutical import market upside down. Using Section 232 of the Trade Expansion Act of 1962, the same national security authority behind steel and aluminum tariffs, the administration imposed tariffs of up to 100% on patented drugs, biologics, and active pharmaceutical ingredients entering the United States.

The justification: America's dependence on foreign-manufactured pharmaceuticals poses a national security threat. The Commerce Department investigation, initiated on April 1, 2025, found that roughly 87% of active pharmaceutical ingredients consumed in the U.S. are manufactured abroad, with China and India dominating the global API supply chain. A disruption — whether from a pandemic, geopolitical conflict, or trade war — could leave American patients without critical medications.

The remedy is the most aggressive tariff action ever aimed at the life sciences sector. And unlike the blunt 10% Section 122 surcharge still in effect on most imports, this one comes with a tiered rate structure so complex that getting it wrong could mean the difference between paying nothing and paying double the value of your shipment.

The Proclamation: What It Covers

The April 2 proclamation targets patented pharmaceutical articles — specifically, products that are subject to a valid, unexpired U.S. patent and listed in either the FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or the FDA's Purple Book (Licensed Biological Products). This includes branded drugs, patented biologics, and the active pharmaceutical ingredients (APIs) and key starting materials used to manufacture them.

What it does not cover is equally important: generic pharmaceuticals, biosimilars, and over-the-counter drugs without valid patents are expressly excluded. This carve-out was intentional — the administration framed the tariffs as targeting the pricing power of large pharmaceutical companies, not the generic supply chain that serves lower-income patients.

The covered products are identified through specific HTSUS codes listed in Annex I of the proclamation. A separate list of exempted products appears in Annex IV, covering a broad range of pharmaceutical chemicals, vitamins, hormones, and antibiotics classified under specific 10-digit tariff codes.

The Five-Tier Rate Structure: Where Do You Fall?

This is where the Section 232 pharma tariffs get genuinely unprecedented. Instead of a single rate, the proclamation creates a tiered framework where your duty depends on three variables: your company's agreements with the U.S. government, the country of origin of the product, and whether you've committed to moving manufacturing to American soil.

The math works as a floating rate. If a covered product already carries a non-duty-free Column 1 MFN rate, the Section 232 tariff is reduced so the combined duty equals the applicable tier rate. If the existing MFN rate already exceeds 100%, no additional Section 232 duty applies. So a product with an existing 30% Column 1 rate and a 20% Section 232 tier would face a combined burden of 30% — the higher of the two, not the sum.

The critical detail: China, India, and Singapore are not listed in any preferential tier. Products originating in those countries default to the 100% rate unless the importing company has its own onshoring or MFN pricing agreement.

The Two Deadlines: July 31 and September 29

The tariffs don't all hit at once. The proclamation creates a staggered timeline based on company size:

• July 31, 2026: Tariffs take effect for the 17 large pharmaceutical companies listed in Annex III. These are the major multinationals the administration identified as having the resources to negotiate quickly. They get 120 days from the proclamation date.

• September 29, 2026: Tariffs take effect for all other companies. Smaller manufacturers and importers get 180 days — an additional 60-day window to negotiate onshoring or MFN pricing agreements.

Companies listed in Annex II — 13 firms that reached agreements with the Secretary of Commerce between December 2025 and March 2026, before the proclamation was even signed — are exempt from additional duties under heading 9903.04.61. These early movers locked in their tariff treatment before the 100% rate was announced.

A joint status report from the Secretaries of Commerce and HHS is due to the President by July 1, 2026 — one month before the first tariffs take effect. That report will likely signal whether additional companies have reached deals and whether the scope of covered products will change.

Why This Matters for Customs Brokers

You might think pharmaceutical tariffs are a problem for Pfizer's trade team, not your brokerage. But the Section 232 pharma framework creates classification and entry challenges that will land squarely on the customs broker's desk.

Classification determines the rate. Whether a product falls under heading 9903.04.60 (100%) or qualifies for 9903.04.61 (exempt), 9903.04.64 (20%), or 9903.04.65 (0%) depends on factors that go beyond standard HTS classification. You need to know whether the importing company has a Commerce onshoring agreement, whether it has an HHS MFN pricing deal, whether the product is patented and listed in the Orange Book or Purple Book, and whether it originates in a trade-deal country.

That's four separate determinations on top of the standard 10-digit classification. Get any one of them wrong, and you've either overpaid or underreported — and CBP will eventually notice both.

Patent status is now a tariff question. Brokers have never had to evaluate patent validity as part of the entry process. But under this framework, the difference between a patented drug (up to 100%) and its generic equivalent (0% Section 232) is the single largest duty variable. Expired patents, patent challenges under Hatch-Waxman, and products transitioning from branded to generic status create a moving target.

Country of origin matters more than ever. A patented drug manufactured in Ireland (EU — 15%) versus India (default — 100%) faces an 85-percentage-point swing in duty rates. For APIs, where manufacturing often involves multi-country supply chains with synthesis in one country and finishing in another, substantial transformation analysis becomes a high-stakes exercise.

The Annex IV Exemptions: Check Before You Pay

Before assuming the worst, check Annex IV of the proclamation. It lists specific HTSUS codes exempt from the entire Section 232 pharma framework — subject to a 0% tariff rate. The exempted categories are broad and include:

• Pharmaceutical chemicals and intermediates
• Vitamins and provitamins
• Hormones and hormone derivatives
• Antibiotics
• Certain pharmaceutical preparations

These exemptions also remove the covered products from the Section 122 temporary import surcharge imposed under Proclamation 11012. If your products fall under Annex IV codes, you're exempt from both the Section 232 pharma tariff and the 10% Section 122 surcharge — a rare double benefit in the current tariff environment.

The catch: Annex IV is a list of specific 10-digit HTS codes, not broad product categories. A slight classification difference — one subheading off — can mean the difference between 0% and 100%. This is exactly the kind of granular classification work where errors cost real money.

What to Do Before July 31

1. Audit your pharmaceutical import portfolio against the Annexes. Pull every pharmaceutical entry you've filed in the last 12 months. Cross-reference the HTS codes against Annex I (covered products), Annex IV (exempt products), and the Chapter 99 headings. Identify which entries would be subject to the new tariffs and at what tier.

2. Determine your clients' agreement status. For every pharmaceutical importer you serve, find out whether they're listed in Annex II (pre-existing agreements), Annex III (large companies with the July 31 deadline), or neither. If they're in active negotiations with Commerce or HHS, get documentation — you'll need it to claim reduced rates at entry.

3. Review country-of-origin determinations for APIs. Active pharmaceutical ingredients often pass through multiple countries during synthesis. If the substantial transformation occurs in an EU member state, Japan, or South Korea, the 15% trade-deal rate applies instead of 100%. For multi-step API manufacturing, origin determination could save your client 85 percentage points.

4. Reassess Foreign-Trade Zone strategies. FTZ operators importing pharmaceutical products should evaluate whether privileged foreign status elections made before the tariff effective date could lock in pre-Section 232 duty treatment. The proclamation doesn't provide transit exceptions — products entered for consumption after July 31 face the new rates regardless of when they shipped.

5. Build a patent monitoring process. You need a way to track when patents expire on products you import. The day a drug goes off-patent, it potentially shifts from the 100% tier to the generic exemption. That's not a classification change — it's a patent-status change that directly affects the duty rate. The FDA's Orange Book and Purple Book are your primary sources.

6. File for duty drawback on re-exports. If your clients import pharmaceutical products and then re-export them (common for multinational supply chains), evaluate whether duty drawback claims can offset some or all of the Section 232 duties. The tariffs apply to the full customs value — drawback could recover a significant portion for products that don't stay in the U.S. market.

What's Coming Next

The Section 232 pharma tariffs are just the opening move. Watch for these developments in the coming weeks:

• July 1, 2026: Joint status report from Commerce and HHS to the President. This will signal whether additional companies have reached deals and whether the scope of covered products changes before the July 31 effective date.
• July 31, 2026: First tariffs take effect for Annex III large companies. Any company that hasn't reached a deal faces 100% duties on that date.
• September 29, 2026: Tariffs extend to all remaining companies. The full weight of the framework takes effect.
• Commerce one-year review: The proclamation directs Commerce to conduct a review of whether generics and biosimilars should remain excluded. If the administration decides the exclusion is being exploited — say, through premature patent abandonment to reclassify products as generics — the exemption could narrow.
• Legal challenges: The use of Section 232 for pharmaceuticals will almost certainly face court scrutiny. Section 232's national security authority has historically been applied to industrial commodities — steel, aluminum, copper. Extending it to patented medications is legally novel, and the pharmaceutical industry has deep pockets for litigation.

The Classification Imperative

The Section 232 pharma tariffs represent something new in customs compliance: a tariff regime where the rate depends not just on what a product is, but on who imports it, what deals they've struck with the government, and whether a patent office filing thousands of miles away is still valid. Traditional HTS classification — matching product characteristics to tariff headings — is necessary but no longer sufficient.

For customs brokers and importers, this is a moment to prove your value. The companies that navigate this framework successfully won't be the ones with the best lawyers (though they'll need those too). They'll be the ones whose trade compliance teams can integrate patent data, country-of-origin analysis, and government agreement tracking into a single classification workflow. TariffLens helps you build exactly that kind of integrated view — connecting HTS codes to the regulatory overlays that determine what you actually pay.

This article is for informational purposes only and does not constitute legal, tax, or customs advice. Consult a licensed customs broker or trade attorney for guidance specific to your situation.